Company Focus
BioNTech
Latest BioNTech News
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to BioNTech
Biotechnology
US biotech Nona Biosciences has entered into a multi-target antibody discovery collaboration with Umoja Biopharma, an immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity. 13 September 2024
Biotechnology
UK pharma major GSK has announced positive headline results from a Phase II trial of its mRNA seasonal influenza vaccine program. 13 September 2024
Biotechnology
US mRNA specialist Moderna was trading 18% lower early in Thursday’s trading. 12 September 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Sanofi’s mega blockbuster drug Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. 12 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
Roivant today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. 10 September 2024
Biotechnology
British pharma major GSK has announced full results from its SWIFT-1 and SWIFT-2 Phase III clinical trials, testing depemokimab. 10 September 2024
Biotechnology
Epsilogen, a specialist in the development of immunoglobulin E (IgE) antibodies to treat cancer, has announced the completion of a £12.5 million ($16.4 million) Series B expansion financing. 9 September 2024
Biotechnology
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Pharmaceutical
Israeli-headquartered RedHill Biopharma has announced the placement of its low-dose rifabutin-triple therapy, Talicia, as an empirically-prescribed fist-line choice for Helicobacter pylori (H. pylori) infection in new American College of Gastroenterology (ACG) guidelines 9 September 2024
Latest In Brief for BioNTech
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
18 October 2024
23 September 2024
19 September 2024
16 September 2024
8 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze